相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways
Qihui Li et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
Alberto Antonicelli et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2013)
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Chee Khoon Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Icaritin Synergistically Enhances the Radiosensitivity of 4T1 Breast Cancer Cells
Jinsheng Hong et al.
PLOS ONE (2013)
Madecassoside suppresses migration of fibroblasts from keloids: involvement of p38 kinase and PI3K signaling pathways
Jie Song et al.
BURNS (2012)
Reactive oxygen species-mediated mitochondrial pathway is involved in Baohuoside I-induced apoptosis in human non-small cell lung cancer
Jie Song et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2012)
Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy
Jen-Yi Lee et al.
PLOS ONE (2011)
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
Tadaaki Yamada et al.
CLINICAL CANCER RESEARCH (2010)
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
Kenichi Suda et al.
CLINICAL CANCER RESEARCH (2010)
Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
A. J. Weickhardt et al.
CURRENT CANCER DRUG TARGETS (2010)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Combined Treatment with Silibinin and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Overcomes Drug Resistance Caused by T790M Mutation
Jin Kyung Rho et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
D. Ercan et al.
ONCOGENE (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients
Barrie R. Cassileth et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Jin Kyung Rho et al.
MOLECULAR CANCER RESEARCH (2009)
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Kornelia Polyak et al.
NATURE REVIEWS CANCER (2009)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation
Wolfgang Sieghart et al.
TRANSPLANTATION (2007)
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions
BR Balsara et al.
CARCINOGENESIS (2004)
分享论文
